Citigroup Upgrades Icon (NASDAQ:ICLR) to Hold

Icon (NASDAQ:ICLR) was upgraded by investment analysts at Citigroup to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Several other equities analysts have also recently weighed in on ICLR. Bank of America raised their price objective on Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research note on Thursday, June 25th. DA Davidson set a $164.00 target price on shares of Icon in a report on Monday, June 1st. JPMorgan Chase & Co. raised their price target on shares of Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a report on Tuesday. Finally, Robert W. Baird set a $194.00 price objective on shares of Icon in a research report on Friday. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $170.40.

Icon Stock Performance

Shares of Icon stock opened at $163.57 on Thursday. Icon has a 52 week low of $66.57 and a 52 week high of $203.91. The company has a quick ratio of 1.14, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The business has a 50 day moving average price of $156.70 and a 200-day moving average price of $135.62. The company has a market cap of $12.52 billion, a PE ratio of 38.40, a price-to-earnings-growth ratio of 8.12 and a beta of 1.22.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, July 29th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same quarter in the previous year, the firm earned $3.26 earnings per share. Icon’s quarterly revenue was up 2.3% on a year-over-year basis. Equities analysts anticipate that Icon will post 9.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Icon

A number of hedge funds have recently made changes to their positions in the business. Harris Associates L P purchased a new position in shares of Icon in the 2nd quarter worth about $238,256,000. Capital World Investors increased its holdings in Icon by 555.2% during the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock worth $272,688,000 after buying an additional 1,268,095 shares during the last quarter. Wellington Management Group LLP increased its holdings in Icon by 26.6% during the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after buying an additional 975,268 shares during the last quarter. Lyrical Asset Management LP bought a new stake in Icon in the fourth quarter worth about $176,382,000. Finally, Norges Bank purchased a new position in Icon in the fourth quarter valued at about $160,073,000. 95.61% of the stock is currently owned by institutional investors.

Key Icon News

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
• Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
• Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
• Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.